5 reasons Iryo will succeed
Iryo’s all-inclusive concept provides new ways of medical data monetization possibilities while at the same time minding the user privacy and security. This is why you won’t regret supporting Iryo.
1. Company recognized on the governmental level
Alongside the community driven recognition, we are now officially recognised by the Government of Slovenia, which highlighted the Iryo project in the “Implementing the 2030 Agenda for Sustainable Development” government report, mentioning Iryo as a company “taking an active part in achieving Sustainable Development Goals in 2018.”
2. A growing developing industry
E-health market is on the rise. Mordor Intelligence predicts an annual growth of 15% till the year 2021, when the market value will reach more than 200 billion USD. Similar to Mordor, Grand View Research Inc predicts the market value to grow up to 250 billion USD by the year 2022. At the same time more and more countries are encouraging the investments from the political point of view, with US, China and Germany leading the pack.
3. Iryo stellar partnerships
Iryo has established several partnerships in the last few months in it’s pursuit of impacting healthcare globally:
- Iryo will provide the IT infrastructure needed to improve the quality of healthcare for the refugees in the camps in the Middle East. The first deployment is predicted to be implemented in Lebanon in May 2018.
- The first practical example of that is the partnership with the Ljubljana Simulation Centre, with which Iryo’s special team of IT-researchers is developing one of the first practical cases of augmented reality in the medical world.
- Iryo is joining forces with Adriatic Slovenica health insurance company (AS) to offer patients in Slovenia better and safer access to their health records.
At the same time, our seed investor is the Slovenian tech company 3fs, we are partnering up with tech companies ZeroPass and Microsoft to further our development, improve on the existing version of Iryo network and reach worldwide implementation.
4. Privacy-first product
Iryo offers an effective and proven answer to the industry-wide problem of secure storage of patient data. Iryo is building a decentralised, zero-knowledge data storage with using blockchain as a permission control tool. Your data. In your hands.
5. Expanding token economy potential
The Iryo token will be used in many ways. You can use it as a patient for medical services inside the Iryo system. You can use it as a researcher to purchase medical data needed for your research.
A rich token ecosystem guarantees frequent and wide token usage. The token usage is focused on frequent events, insuring an active and vibrant market.
With a vision of building a strong company, Iryo is allocating 90% of the tokens to the community. As part of the 2% yearly inflation, Iryo will dedicate a minimum of 50% of the newly minted Iryo tokens to internal or external medical R&D initiatives that will pave the way for new innovative products.
Find out more!
Legal disclaimer:
IRYO tokens are not being structured or sold as securities or any other form of investment product, are not intended to be a legal tender, security, commodity, or any other kind of financial instrument. Accordingly, none of the information presented in this press release is intended to form the basis for any investment decision, and no specific recommendations are intended. This post is available for information purposes only and does not constitute investment advice or counsel or solicitation in any financial instrument. Furthermore, this post does not constitute any recommendation, offer or invitation to buy, sell or subscribe any financial instrument. IRYO expressly disclaims any and all responsibility for any direct or consequential loss or damage of any kind whatsoever arising directly or indirectly from: (i) reliance on any information contained in this press release (ii) any error, omission or inaccuracy in any such information or (iii) any action resulting from such information.
This post contains certain forward-looking statements. These are based on analyses or forecasts of future results, estimates of amounts and circumstances not yet determinable or foreseeable. Such forward-looking statements in this press release are based on current estimates and assumptions that IRYO makes to the best of its present knowledge. Such forward-looking statements are subject to risks, uncertainties and other factors which could cause actual developments to differ materially from and be worse than expected or assumed or described in these forward-looking statements. In light of these risks, uncertainties and assumptions, future events described in this press release may not occur. In addition, IRYO does not assume any obligation, except as required by applicable statutory law, to update any forward-looking statements or to confirm these forward-looking statements to actual events or developments.
